Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.

US-based autoimmune disease and cancer drug developer Abcuro has completed a $42m series A-1 round co-led by investment vehicles for pharmaceutical firm Sanofi and healthcare provider Mass General Brigham. Sanofi Ventures and Mass General Brigham Ventures were joined in the round by Pontifax Venture Capital, Hongsen Investment Group, RA Capital Management and Samsara BioCapital. Abcuro…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.